The Indian Pharmaceutical Market (IPM) has registered a growth of 6.9 per cent during November 2013 and reached at Rs.
6,291 crore as per 'AIOCD AWACS', a pharmaceutical market research
organisation that has evolved into an IT infrastructure player in Pharma
Distribution & Retail, monthly figures. Sun Pharmaceuticals, which
reported consolidated net sales of Rs. 11,200 crore plus in 2012-13, has grabbed highest position with sales of Rs. 357 crore during November 2013, followed by Cipla at Rs. 328 crore and Zydus Cadila at Rs.
262 crore. The sales of Sun Pharmaceuticals increased by 17.1 per cent
and that of Cipla moved up by 12.2 per cent. Glenmark, Ipca
Laboratories, Emcure, Alembic Cadila, Eris and Meyer Organics have
registered growth of over 25 per cent during November 2013.
After
three continuous months of volume degrowths, the IPM market witnessed a
seasonal change with once again the numbers coming to positive for the
months of November 2013. The price growth component was at 0.8 per cent
thereby signifying the impact of price cuts witnessed due to the
implementation of the pricing policy. The leading brands like Phensedyl
clocked a growth of 63 per cent followed by Glycomet-GP 62 per cent,
Moxikind -VC 33 per cent and Clavam 29 per cent.
However, the
volume growths that was seen in the last years is still far off. The
growth driver split shows positive on the parameter of volume & new
introductions leading to overall positive growths over October 2012.
The
DPCO 2013 containing molecules market was negative at 8.6 per cent
whereas the non DPCO market grew by 9.5 per cent resulting in an overall
growth of 6.9 per cent. The DPCO 2013 portfolio for GlaxoSmithKline
Pharma declined by 31.8 per cent and that of Ranbaxy Laboratories
declined by 20.7 per cent. However, Sun Pharma had the least impact with
its DPCO 2013 portfolio degrowing at 6.8 per cent.
As per the
report, eight therapies have outgrown the IPM growth. Gastrointestinal
market grew at 8.4 per cent, anti-infective market had a growth of 2.6
per cent, whereas respiratory market had a 15.1 per cent growth.
Anti-diabetic market moved up by 6.1 per cent and cardiac at 7.2 per
cent in chronic business. Anti-malarials increased by 21.2 per cent and
Derma market up by 15.2 per cent.
Total eleven regions have
outgrown in IPM growth and Bihar growth was up by 16.6 per cent and
Delhi by 16.4 per cent. However, biggest region Tamil Nadu degrew at 7.5
per cent and AP Rest degrew by 5.2 per cent. The biggest molecule
amozycillin and clavulanic increased by 9.7 per cent and cefixime also
moved up at 2.3 per cent. Paracetamol and azithromycin grew at 5.1 per
cent and 2.7 per cent respectively. The market of vitamin-D increased
sharply by 49.5 per cent and that of glimepiride and metformin improved
by 40.8 per cent. Rosuvastain, levocetirizine and montelukast &
telmisartan up by 22 per cent.
Source: PharmaBiz
